Videos

“About three-quarters of urologists reported barriers to professional success,” says Christina Shin.

Sam S. Chang, MD, MBA, recaps 5 presentations from the 2022 American Society of Clinical Oncology Annual Meeting.

“What was published in May of 2022 was version 4 of the 2022 guidelines,” says Edward M. Schaeffer, MD, PhD.

“I think most panelists are happy to participate in those meetings, because generally speaking, those ad hoc meetings are done because there's a new advance in the field,” says Edward M. Schaeffer, MD, PhD.

“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.

“What’s really exciting over the next few years is how are these antibody-drug conjugates that are already FDA-approved going to partner with other current drugs that we can use to treat this disease, such as immunotherapy,” says Garmezy.

“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.

"A key overarching question is whether there is just a higher burden/stage of disease “beyond which we don’t think a bladder preservation is likely to provide durable disease control,” says Neil Desai, MD.

“We recognize that we now have tools we didn't previously have that allow us to make some major changes,” says David Joseph, MD.

“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.

“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.

“Your best bladder is the one you were born with,” says Neil Desai, MD.

“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.

Understanding the mechanisms of treatment resistance is among the areas of unmet need, says James Brugarolas, MD, PhD.

Tivozanib (Fotivda) is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

“It’s important for men to be aware that there are scientific mechanisms through which COVID-19 can affect male sexual function and male reproductive function," says Hossein Sadeghi-Nejad, MD.

“The implications of the findings are that the SUI literature is, perhaps, not as good as it could be, but there’s hope,” says Eric S. Rovner, MD.

Antegrade mitomycin gel instillation was done through a percutaneous nephrostomy tube.

In the first interview of the series, Judd W. Moul, MD, provides an overview of the management of mHSPC and mCRPC including key considerations in the use of the androgen deprivation therapy leuprolide with or without novel hormone therapy or chemotherapy.

Philippe Spiess, MD, Moffitt Cancer Center, discusses the latest developments in the evolving treatment paradigm for patients with penile cancer.

Based on previously reported CheckMate-274 data, the FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma.

“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.

Joshua J. Meeks, MD, PhD, recaps several presentations on bladder cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.

Ashley E. Ross, MD, PhD, recaps several presentations on prostate cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

Philippe Spiess, MD, MS, FACS, recaps several presentations from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.

“When you're talking about ‘impact,’ I don't think it gets any bigger than treating male infertility, because you're surgically treating the man, of course, but you're really treating the couple as a whole, and you're helping potentially create a new life,” says Justin Dubin, MD.

In the first video of the series, Jennifer A. Linehan, MD, provides an overview of LG-UTUC including risk factors, signs and symptoms, and diagnosis as well as factors to consider regarding disease progression, recurrence, and which patients might be candidates for resection.

Guru P. Sonpavde, MD, discusses the 2022 ASCO Annual Meeting abstract, “Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.”

Phillip Kuo, MD, PhD, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.